Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Mixed salts of a single-entity amphetamine
Takeda Pharmaceuticals International AG
Attention Deficit Disorder With Hyperactivity
1 trial -
Mixed salts of a single-entity amphetamine (ADDERALL XR)
Takeda Pharmaceuticals International AG
ADHD
1 trial -
Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
Takeda Pharmaceuticals International AG
Attention Deficit Disorder With Hyperactivity
4 trials -
VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine Dependence
1 trial -
extended-release naltrexone (XR-NTX)
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine-dependence
1 trial -
3,4-Methylenedioxymethamphetamine (MDMA)
United Therapeutics Europe Ltd
Post Traumatic Stress Disorder
1 trial -
Atomoxetine
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Dependence
1 trial -
Behavior Therapy
BRIGHT MINDS BIOSCIENCES INC.
The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings
1 trial -
Bupropion
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Dependence
1 trial -
Bupropion
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine-Related Disorders
2 trials -
Bupropion
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine
1 trial -
Bupropion SR 150mg tabs
BRIGHT MINDS BIOSCIENCES INC.
Adolescent Methamphetamine Abuse
1 trial -
CPP-109 vigabatrin
CATALYST PHARMACEUTICALS, INC.
Methamphetamine Dependence
1 trial -
D-Amphetamine 30mg
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Dextro-Amphetamine Sulfate
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Dextroamphetamine
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
4 trials -
Doxazosin extended release
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine or Cocaine Dependence
1 trial -
Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Use Disorder
1 trial -
Ibudilast
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Dependence
1 trial -
Intermittent Oral Naltrexone
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine
1 trial -
Methamphetamine
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Intoxication
1 trial -
Mirtazapine
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine-Related Disorders
1 trial -
Mixed-Amphetamine Salts- Extended Release (MAS-ER)
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Dependence
1 trial -
Modafinil
BRIGHT MINDS BIOSCIENCES INC.
Methamphetamine Dependence
2 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources